40
views
0
recommends
+1 Recommend
3 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Distinct characteristics of COVID‐19 patients with initial rRT‐PCR‐positive and rRT‐PCR‐negative results for SARS‐CoV‐2

      letter

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To the Editor, Since the coronavirus disease 2019 (COVID‐19) caused by SARS‐CoV‐2 (severe acute respiratory syndrome coronavirus 2) first emerged in Wuhan, China, in December 2019, the outbreak of COVID‐19 epidemic has become an increasingly serious global health concern. Currently, over 150 countries have reported COVID‐19 cases, and the situation has progressed to a pandemic associated with substantial morbidity and mortality. 1 At present, rRT‐PCR (real‐time reverse transcription–polymerase chain reaction) assay is the most common and only direct method of SARS‐CoV‐2 detection for the diagnosis of COVID‐19. 2 However, false‐negative results due to laboratory errors or improper collection of the specimens may inevitably lead to an important percentage of undiagnosed COVID‐19 patients. Some patients with suspected COVID‐19 have initial negative result of the rRT‐PCR test 3 , 4 or low viral concentration of SARS‐CoV‐2 at the sampling site in the early stages of the disease. 5 This study aims to compare the clinical and laboratory characteristics of eventually confirmed COVID‐19 patients with initial positive and negative SARS‐CoV‐2 nucleic acid test results. The present study retrospectively reports 290 laboratory‐confirmed COVID‐19 patients hospitalized from December 29, 2019, to February 16, 2020. According to initial rRT‐PCR results, patients were divided into initial positive and negative groups. All rRT‐PCR assays were performed with the same kit (Shanghai bio‐germ Medical Technology Co Ltd). Electronic medical records, including patients’ demographics, clinical manifestation, comorbidities, laboratory results, and radiological materials on admission were collected and analyzed. The clinical outcomes of each patient were reviewed and analyzed on the final follow‐up (February 28, 2020) including disease severity, complications, and co‐infection status with other pathogens during hospitalization. This study was approved by the Zhongnan Hospital of Wuhan University institutional ethics board (No.2020015 and No. 2020028). Additional details on the methods are reported in the Supporting Information. Of the 290 patients involved in this study, an initial rRT‐PCR test was positive for SARS‐CoV‐2 by 249 (85.9%) patients and negative by 41 (14.1%) patients. Among the 41 patients with an initial negative result, 21 tested positive at the second rRT‐PCR test and 13 of them became positive at the third test. The cumulative positive ratio of rRT‐PCR assay of these 41 patients from the 2nd time to the 5th time of the test gradually increased from 51.2% (21/41) to 82.9% (34/41), 92.7% (38/41), and 97.6% (40/41) (Figure 1A), and the rRT‐PCR‐positive ratio of all 290 patients by the 5th test was 99.7% (289/290) (Figure 1B). Figure 1 Number of patients testing positive for SARS‐CoV‐2 and the cumulative positive ratio at different rRT‐PCR tests. A, Changes in the outcome of the rRT‐PCR test of patients, from negative to positive, after consecutive assays. Of the 41 patients with an initial negative result, 21, 13, 4, 2, and 1 patients were tested positive at the 2nd, 3rd, 4th, 5th, and 6th rRT‐PCR assays, respectively. The cumulative positive rRT‐PCR assay ratio from the second to the fifth test increased from 51.2% (21/41) to 97.6% (40/41). B, Number and percentage of positive results within the total patient population. The cumulative positive ratio of all 290 patients from the first to the fifth test increased from 85.9% (249/290) to 99.7% (289/290). rRT‐PCR, real‐time reverse transcription–polymerase chain reaction The median age of the patients was 57 years (range, 22‐88 years), and 184 (63.5%) were aged over 50 years (Table 1). Of the 290 patients, 155 (53.4%) patients were male, but the majority [25 (61%)] of the patients with initial negative rRT‐PCR results were female. Of the 89 (30.7%) patients with surgery history, the proportion of patients with an initial positive rRT‐PCR result was significantly higher than that of patients with an initial negative rRT‐PCR result (32.9% vs 17.1%, P = .041). Table 1 Demographics and partial clinical data of patients with COVID‐19   All Patients (n = 290) Initial result of SARS‐CoV‐2 rRT‐PCR test Positive (n = 249) Negative (n = 41) P value Age—median (range) 57 (22‐88) 57 (22‐88) 51 (22‐79) .089 Age groups ‐No. (%) <30 y 16 (5.5) 11 (4.4) 5 (12.2) .165 30‐49 y 90 (31.0) 76 (30.5) 14 (34.1) ‐ 50‐69 y 120 (41.4) 107 (43) 13 (31.7) ‐ ≥70 y 64 (22.1) 55 (22.1) 9 (22.0) ‐ Sex—No. (%) Female 135 (46.6) 110 (44.2) 25 (61.0) .062 Male 155 (53.4) 139 (55.8) 16 (39.0) ‐ Exposure History—No. (%) Yes 83 (28.6) 74 (29.7) 9 (22.0) .308 No 207 (71.4) 175 (70.3) 32 (78.0) ‐ Comorbidity—No. (%) 178 (61.4) 158 (63.5) 20 (48.8) .074 Hypertension 81 (27.9) 68 (27.3) 13 (31.7) .561 Diabetes mellitus 27 (9.3) 25 (10) 2 (4.9) .393 Coronary heart disease 18 (6.2) (6.2) 18 (7.2) 0 (0.0) .087 Drug hypersensitivity (self‐reported) 10 (3.4) 10 (4.0) 0 (0.0) .367 COPD 6 (2.1) 6 (2.4) 0 (0.0) .600 Urticaria 2 (0.7) 1 (0.4) 1 (2.4) .263 Asthma 1 (0.3) 1 (0.4) 0 (0.0) >.999 Others 72 (24.8) 66 (26.5) 6 (14.6) .103 Surgery history—No. (%) 89 (30.7) 82 (32.9) 7 (17.1) .041 Tumor surgery 15 (5.2) 15 (6.0) 0 (0.0) .141 Craniocerebral surgery 6 (2.1) 6 (2.4) 0 (0) .600 Cardiac intervention 10 (3.4) 10 (4.0) 0 (0) .367 Others 62 (21.4) 55 (22.1) 7 (17.1) .468 Smokers—No. (%) 28 (9.7) 25 (10) 3 (7.3) .778 Past Smokers 18 (6.2) 16 (6.4) 2 (4.9) >.999 Current Smokers 10 (3.4) 9 (3.6) 1 (2.4) >.999 Severity—No. (%) Severe 121 (41.7) 111 (44.6) 10 (24.4) .015 Nonsevere 169 (58.3) 138 (55.4) 31 (75.6) ‐ Note COVID‐19, coronavirus disease 2019; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2; rRT‐PCR, real‐time reverse transcription–polymerase chain reaction; COPD, chronic obstructive pulmonary disease; P values denote the statistical significance between initially positive and negative result subgroups. John Wiley & Sons, Ltd This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency. Compared to patients with an initial negative rRT‐PCR result, patients with an initial positive result were more likely to progress to a severe condition (44.6% vs 24.4%, P = .015) (Table 1). In 226 patients with available chest CT images, 214 (94.7%) had typical patterns of COVID‐19, and the proportions for initially positive and negative patients with abnormal CT images were 94.2% (180/191) and 97.1% (34/35), respectively. On February 28th, out of the 290 patients, 189 (65.2%) were discharged and, unfortunately, 46 (15.9%) did not survive. The mortality of patients with an initial negative rRT‐PCR result [5 (12.2%)] was slightly lower than those with a positive result [41 (16.5%)], whereas the proportion of discharged patients from the negative group [32 (78%)] tended to be larger than the positive group [157 (63.1%)], without any statistically significant difference (Table S1). The laboratory results of patients on admission are shown in Table S2. Among 290 patients, leukopenia (n = 78, 26.9%), neutropenia (n = 51, 17.6%), lymphopenia (n = 203, 70.0%), eosinopenia (n = 171, 59.0%), and thrombocytopenia (n = 65, 22.4%) were observed, without any significant difference between patients with initial positive and negative rRT‐PCR results. Elevated levels of C‐reactive protein (n = 249, 88%), serum amyloid A (n = 149, 84.2%), procalcitonin (n = 85, 31.1%), D‐dimer (n = 105, 45.3%), and serum creatine kinase (n = 30, 15.7%) were found. No significant difference was seen between the initial positive and negative patients within these acute phase reactants (all P > .05) (Table S2). In general, except for two aspects (surgery history and severity), no significant difference was observed in clinical manifestations, laboratory findings, and radiological changes between patients with initial positive and negative rRT‐PCR results in the present study. Similar results were reported by Li et al and Lu et al, 6 , 7 where patients with a positive rRT‐PCR test appeared to have increased disease severity, although the differences were not statistically significant in Li's (35.5% vs 13%, P = .063) and Lu's (20.8% vs 13.7%, P = .20) study. Surgery history may be a confounding factor in this study, which may also relate to factors such as age and sex. The findings of further logistic regression analysis showed no predictive value for the history of surgery. Previous studies suggested that a false‐negative rRT‐PCR result may occur in some COVID‐19 patients. 3 , 4 False‐negative results may occur as a result of various factors, such as human errors when following the diagnostic kit protocol, the sensitivity of reagents, the site and method of specimen sampling and collection times. 8 It should be noted that a fraction of initial rRT‐PCR negative results may be due to low or no virus expression in the sampled area. In regard to the site of specimen sampling, it has been previously reported that the viral load in the nose is higher than in the pharynx, and the virus detection rate in the lower respiratory tract is higher than in the upper respiratory tract. 9 Currently, most samples are collected from the upper respiratory tract, such as oropharynx swabs, due to ease of sampling or absence of sputum in the patient, which may lead to false‐negative rRT‐PCR results. Another important point to emphasize here is that the same errors for initial negative results can occur at the time of decision to discharge for clinically healed patients. As can be seen, the patients involved in the study are all hospitalized cases and we had a chance to further confirm the data with clinical diagnosis and repeated rRT‐PCR tests. Some of the false‐positive results can be because of low virus expression in pharynx samples, which can be even higher percentages in nonhospitalized cases. In this context, the isolation of COVID‐19 suspected patients should be more vigorous and the decision should not only depend on rRT‐PCR positivity during the time of the pandemics. The findings presented herein suggest that a considerable proportion of COVID‐19 patients may have an initial negative rRT‐PCR result and that initially positive patients had a higher tendency to progress to severe cases. Therefore, diagnosis of SARS‐CoV‐2 infection should not be excluded in patients with an initial negative rRT‐PCR result, especially when presented with typical clinical manifestations. In view of these results, we recommend repeated rRT‐PCR tests to confirm diagnosis and identify potentially infected individuals. CONFLICT OF INTEREST The authors have no conflict of interest. Supporting information Sup info Click here for additional data file.

          Related collections

          Most cited references5

          • Record: found
          • Abstract: found
          • Article: found

          Detection of SARS-CoV-2 in Different Types of Clinical Specimens

          This study describes results of PCR and viral RNA testing for SARS-CoV-2 in bronchoalveolar fluid, sputum, feces, blood, and urine specimens from patients with COVID-19 infection in China to identify possible means of non-respiratory transmission.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Chest CT for Typical 2019-nCoV Pneumonia: Relationship to Negative RT-PCR Testing

            Some patients with positive chest CT findings may present with negative results of real time reverse-transcription–polymerase chain- reaction (RT-PCR) for 2019 novel coronavirus (2019-nCoV). In this report, we present chest CT findings from five patients with 2019-nCoV infection who had initial negative RT-PCR results. All five patients had typical imaging findings, including ground-glass opacity (GGO) (5 patients) and/or mixed GGO and mixed consolidation (2 patients). After isolation for presumed 2019-nCoV pneumonia, all patients were eventually confirmed with 2019-nCoV infection by repeated swab tests. A combination of repeated swab tests and CT scanning may be helpful when for individuals with high clinical suspicion of nCoV infection but negative RT-PCR screening
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Use of Chest CT in Combination with Negative RT-PCR Assay for the 2019 Novel Coronavirus but High Clinical Suspicion

              Online supplemental material is available for this article. A 36-year-old man presented to the hospital with a 2-day history of fever, sore throat, and fatigue 5 days after visiting Wuhan, China. His temperature on admission was 37.8°C (100.04°F). Pulmonary auscultation was normal. Laboratory studies showed a normal white blood cell count (4.6 × 109/L) with a differential count of 53.1% neutrophils. The blood procalcitonin level was normal. Chest CT showed multiple peripheral ground-glass opacities in both lungs with more involvement of the left upper lobe, lingular segment (Figure a–c). At admission, the real-time fluorescence polymerase chain reaction (RT-PCR) assay of the sputum was negative for the 2019 novel coronavirus (2019-nCoV) nucleic acid. Figure a: Images in a 36-year-old man with a 2-day history of fever, sore throat, and fatigue 5 days after visiting Wuhan, China, and a negative sputum real-time fluorescence polymerase chain reaction assay for the 2019 novel coronavirus. (a, b) Chest CT scans obtained at presentation show ground-glass opacities (red box) in the right upper lobe and the lingular segment and left lower lobe (b). (c) Volume rendering of chest CT scan obtained at admission. (d, e) CT scans obtained 3 days after admission show progression of ground-glass opacities to an atoll sign in the right upper lobe (red boxes in d) and left lower lobe consolidation (red boxes in e). (f) Volume rendering of chest CT scan obtained 3 days after admission shows the new areas of consolidation. See also Movies 1 and 2 (online) Figure b: Images in a 36-year-old man with a 2-day history of fever, sore throat, and fatigue 5 days after visiting Wuhan, China, and a negative sputum real-time fluorescence polymerase chain reaction assay for the 2019 novel coronavirus. (a, b) Chest CT scans obtained at presentation show ground-glass opacities (red box) in the right upper lobe and the lingular segment and left lower lobe (b). (c) Volume rendering of chest CT scan obtained at admission. (d, e) CT scans obtained 3 days after admission show progression of ground-glass opacities to an atoll sign in the right upper lobe (red boxes in d) and left lower lobe consolidation (red boxes in e). (f) Volume rendering of chest CT scan obtained 3 days after admission shows the new areas of consolidation. See also Movies 1 and 2 (online) Figure c: Images in a 36-year-old man with a 2-day history of fever, sore throat, and fatigue 5 days after visiting Wuhan, China, and a negative sputum real-time fluorescence polymerase chain reaction assay for the 2019 novel coronavirus. (a, b) Chest CT scans obtained at presentation show ground-glass opacities (red box) in the right upper lobe and the lingular segment and left lower lobe (b). (c) Volume rendering of chest CT scan obtained at admission. (d, e) CT scans obtained 3 days after admission show progression of ground-glass opacities to an atoll sign in the right upper lobe (red boxes in d) and left lower lobe consolidation (red boxes in e). (f) Volume rendering of chest CT scan obtained 3 days after admission shows the new areas of consolidation. See also Movies 1 and 2 (online) Figure d: Images in a 36-year-old man with a 2-day history of fever, sore throat, and fatigue 5 days after visiting Wuhan, China, and a negative sputum real-time fluorescence polymerase chain reaction assay for the 2019 novel coronavirus. (a, b) Chest CT scans obtained at presentation show ground-glass opacities (red box) in the right upper lobe and the lingular segment and left lower lobe (b). (c) Volume rendering of chest CT scan obtained at admission. (d, e) CT scans obtained 3 days after admission show progression of ground-glass opacities to an atoll sign in the right upper lobe (red boxes in d) and left lower lobe consolidation (red boxes in e). (f) Volume rendering of chest CT scan obtained 3 days after admission shows the new areas of consolidation. See also Movies 1 and 2 (online) Figure e: Images in a 36-year-old man with a 2-day history of fever, sore throat, and fatigue 5 days after visiting Wuhan, China, and a negative sputum real-time fluorescence polymerase chain reaction assay for the 2019 novel coronavirus. (a, b) Chest CT scans obtained at presentation show ground-glass opacities (red box) in the right upper lobe and the lingular segment and left lower lobe (b). (c) Volume rendering of chest CT scan obtained at admission. (d, e) CT scans obtained 3 days after admission show progression of ground-glass opacities to an atoll sign in the right upper lobe (red boxes in d) and left lower lobe consolidation (red boxes in e). (f) Volume rendering of chest CT scan obtained 3 days after admission shows the new areas of consolidation. See also Movies 1 and 2 (online) Figure f: Images in a 36-year-old man with a 2-day history of fever, sore throat, and fatigue 5 days after visiting Wuhan, China, and a negative sputum real-time fluorescence polymerase chain reaction assay for the 2019 novel coronavirus. (a, b) Chest CT scans obtained at presentation show ground-glass opacities (red box) in the right upper lobe and the lingular segment and left lower lobe (b). (c) Volume rendering of chest CT scan obtained at admission. (d, e) CT scans obtained 3 days after admission show progression of ground-glass opacities to an atoll sign in the right upper lobe (red boxes in d) and left lower lobe consolidation (red boxes in e). (f) Volume rendering of chest CT scan obtained 3 days after admission shows the new areas of consolidation. See also Movies 1 and 2 (online) Movie 1: Volume rendering of chest CT scan obtained at admission (see Figure c). Movie 2: Volume rendering of chest CT scan obtained 3 days after admission shows the new areas of consolidation (see Figure f). Repeat CT chest performed 3 days after admission showed transformation of ground-glass opacities to more consolidation (Figure d–f). A repeat RT-PCR 2019-nCoV nucleic acid assay was also negative at this time. Six days after admission, the third RT-PCR 2019-nCoV nucleic acid assay was finally found to be positive. When specimen tests are negative, the possibility of a false-negative result should be considered in the context of a patient’s recent exposures and the presence of clinical signs and symptoms consistent with 2019-nCoV infection (1,2). In this case, chest CT findings were typical of findings for 2019-nCoV pneumonia (3) coupled with recent exposure suggesting that 2019-nCoV infection was likely.
                Bookmark

                Author and article information

                Contributors
                akdisac@siaf.uzh.ch
                gaoyadong@whu.edu.cn
                Journal
                Allergy
                Allergy
                10.1111/(ISSN)1398-9995
                ALL
                Allergy
                John Wiley and Sons Inc. (Hoboken )
                0105-4538
                1398-9995
                27 April 2020
                : 10.1111/all.14316
                Affiliations
                [ 1 ] Department of Allergology Zhongnan Hospital of Wuhan University Wuhan China
                [ 2 ] Department of Radiology Zhongnan Hospital of Wuhan University Wuhan China
                [ 3 ] Department of Gastroenterology Zhongnan Hospital of Wuhan University Wuhan China
                [ 4 ] Department of Infectious Disease No.7 Hospital of Wuhan Wuhan China
                [ 5 ] Swiss Institute of Allergy and Asthma Research (SIAF) University of Zurich Davos Switzerland
                Author notes
                [*] [* ] Correspondence

                Ya‐dong Gao, Department of Allergology, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei, China.

                Email: gaoyadong@ 123456whu.edu.cn

                Cezmi A. Akdis, Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Herman‐Burchard Strasse 9, 7265, Davos, Switzerland.

                Email: akdisac@ 123456siaf.uzh.ch

                Author information
                https://orcid.org/0000-0002-4414-866X
                https://orcid.org/0000-0002-5241-4307
                https://orcid.org/0000-0001-8020-019X
                https://orcid.org/0000-0003-1251-7608
                Article
                ALL14316
                10.1111/all.14316
                7262033
                32281110
                96605cc4-2de2-4965-a736-05befd162451
                © 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

                This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

                History
                : 27 March 2020
                : 06 April 2020
                : 06 April 2020
                Page count
                Figures: 1, Tables: 1, Pages: 4, Words: 4643
                Categories
                Letter to the Editor
                Letters to the Editor
                Custom metadata
                2.0
                corrected-proof
                Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.3 mode:remove_FC converted:01.06.2020

                Immunology
                Immunology

                Comments

                Comment on this article